ICON plc

ICON provides outsourced development and commercialization services globally. The company specializes in clinical development programs from compound selection to Phase I-IV studies. Services include clinical trial management, consulting, contract staffing, data solutions, and site access. Additionally, ICON offers laboratory services, including bionanalytical and central lab services. The company also provides adaptive trials, cardiac safety solutions, and real-world intelligence. ICON serves pharmaceutical, biotechnology, medical device industries, government, and public health organizations. Headquartered in Dublin, Ireland since 1990.

Overview

Sector

Healthcare

Target Price

284.0 USD

Current Price

155.4 USD

Potential

83%

Strengths

With an appreciation Potential of 71.06%, based on our fundamental analysis, it suggests the stock may be undervalued.
Current Price to Earnings Ratio (16.94) is lower than the sector mean (67.88).
Price to book ratio (1.41) is lower than the sector mean (9.96).
EV/EBITDA (9.67) is lower than the sector mean (36.02).
EV/EBIT (15.15) is lower than the sector mean.
Price to free cash flow (11.98) is lower than the sector mean.
Strong EBITDA Margin of 20.35%.

Weaknesses

The company has high debt. Net Debt to EBITDA Ratio (1.71) is higher than the sector mean.

Key Financial Data

Indicator	Value
PER	15.9
EV/EBITDA	9.2
Price/Free Cash Flow'	11.2
ROIC	9.9%
Net Debt/EBITDA	1.7